Octane Medical Group to Acquire Lonza’s Personalized Medicine Business
March 4, 2026
Octane Medical Group entered into a definitive agreement to acquire Lonza’s Personalized Medicine business, including Lonza’s controlling stake in the Cocoon cell-therapy platform plus related intellectual property, workforce, and existing customer contracts. The transaction is expected to close by the end of Q1 2026, subject to customary closing conditions.
- Buyers
- Octane Medical Group
- Targets
- Lonza's Personalized Medicine business, Cocoon cell-therapy platform (Cocoon Platform; controlling stake held by Lonza)
- Sellers
- Lonza
- Industry
- Healthcare Services
- Location
- Ontario, Canada
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.